![]() |
Herceptin® (trastuzumab) delivery methods: an interview with Dr Gustavo Ismael
Approximately 20% of all breast cancer patients have overexpression of HER2 (human epidermal growth factor receptor 2), resulting in a more aggressive phenotype, and a poor prognosis.
More... |
| All times are GMT -7. The time now is 11:17 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021